A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Everolimus (Primary) ; Temsirolimus (Primary) ; Vemurafenib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 02 Apr 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 02 Apr 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 10 Jun 2017 Biomarkers information updated